Hiroya Takiuchi
About
In The Last Decade
Hiroya Takiuchi
85 papers receiving 2.8k citations
Hit Papers
Peers
Comparison fields: 5 of 104
- Pulmonary and Respiratory Medicine 2.1k
- Oncology 1.4k
- Surgery 1.3k
- Gastroenterology 584
- Molecular Biology 353
Countries citing papers authored by Hiroya Takiuchi
This map shows the geographic impact of Hiroya Takiuchi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Hiroya Takiuchi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Hiroya Takiuchi more than expected).
Fields of papers citing papers by Hiroya Takiuchi
This network shows the impact of papers produced by Hiroya Takiuchi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Hiroya Takiuchi. The network helps show where Hiroya Takiuchi may publish in the future.
Co-authorship network of co-authors of Hiroya Takiuchi
This figure shows the co-authorship network connecting the top 25 collaborators of Hiroya Takiuchi. A scholar is included among the top collaborators of Hiroya Takiuchi based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Hiroya Takiuchi. Hiroya Takiuchi is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
| # | Work | Indexed citations |
|---|---|---|
| 1 | Guidelines for Diagnosis and Treatment of Carcinoma of the Esophagus April 2012 edited by the Japan Esophageal Society breakdown → | 348 |
| 2 | 7 | |
| 3 | 33 | |
| 4 | 20 | |
| 5 | 33 | |
| 6 | 11 | |
| 7 | 32 | |
| 8 | 43 | |
| 9 | 10 | |
| 10 | Fluorouracil versus combination of irinotecan plus cisplatin versus S-1 in metastatic gastric cancer: a randomised phase 3 study breakdown → | 472 |
| 11 | 89 | |
| 12 | 24 | |
| 13 | 21 | |
| 14 | 28 | |
| 15 | 5 | |
| 16 | 83 | |
| 17 | 9 | |
| 18 | 83 | |
| 19 | 1 | |
| 20 | 0 |
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.